Taltz (ixekizumab)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Taltz (ixekizumab)

How to buy Taltz: You can order Taltz (ixekizumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Eli Lilly and Co.
Disease Psoriasis
Indication Plaque psoriasis
Mode of Action Humanised interleukin-17A antagonist
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Strength 80 mg/mL

Who is ixekizumab for?

Taltz (ixekizumab) is indicated for the treatment of patients with moderate to severe plaque psoriasis [1] who are candidates for systemic therapy or phototherapy [2][3].

Recommended dose

Complete information about Taltz (ixekizumab) dosage and administration can be found here: [4][2][3].
The standard dosage is:
  • first dose of 160 mg (two injections)
  • for the first 12 weeks: an injection of 80 mg every 2 weeks
  • thereafter an injection of 80 mg every 4 weeks.
Instruction for the use of the prefilled syringe can be found here [5], whilst instructions for the use of the prefilled pen can be found here [6].
Consult your treating doctor for personalised dosing.

What is ixekizumab and how does it work?

Taltz (ixekizumab) is a monoclonal antibody used to treat adults with moderate to severe plaque psoriasis [1][2][3].
The active ingredient in Taltz, ixekizumab, is a humanised interleukin-17A antagonist [2]; a protein designed to attach to interleukin 17A, a messenger molecule in the immune system. Interleukin 17A is involved in immune system effects, including inflammation, that cause psoriasis. By attaching to interleukin 17A, ixekizumab blocks its action and reduces the activity of the immune system, thereby reducing the symptoms of psoriasis [1].

What is ixekizumab's approval status?

Ixekizumab was approved by:
  • FDA (USA) on March 22, 2016 [2]
  • EMA (EU) on May 2, 2016 [1]
  • TGA (AUS) on September 6, 2016 [3]
for the treatment of adults with moderate to severe plaque psoriasis.
The approvals were based on 3 main clinical trials (UNCOVER-1,2,3) involving 3,866 patients with psoriasis [2][3][4]. All 3 studies compared ixekizumab administered at a dosage of 80 mg (after an initial injection of 160 mg) every 2 (N = 1169) or every 4 weeks (N= 1165), with placebo (N= 792). Two trials compared ixekizumab also to etanercept (N = 740). The parameters used for the comparison were the static Physician Global Assessment (sPGA)  and the Psoriasis Area and Severity Index (PASI) [4][2]. The sPGA is a measure of the status of the psoriatic lesions of a patient (i.e., plaque thickness/induration, erythema, scaling) on a severity scale from 0 (=clear) to 5 (=severe) [5]. The PASI additionally to the severity of the lesions takes into account the body surface area covered with psoriatic lesions [7]. The results presented here are the average across the 3 studies, the complete results can be found here: [4][2].
After 12 weeks ixekizumab administered every 2 weeks resulted as superior in all the measured parameters to all other tested conditions. The sPGA was equal to 0 (=clear) or 1 (=almost clear) in 81.8 % of the patients treated with ixekizumab every 2 weeks and almost 40 % of these had clear skin (sPGA =1 in 39.7 % of the patients and 37.8 % had a reduction of 100 % in PASI). On the other hand the sPGA was equal to 0 or 1 in 74.9 % of the patients treated with ixekizumab every 4 weeks, 38.8 % of those treated with etanercept and 4.1 % in the placebo cohort [4]. Almost 89 % of those treated every two weeks with ixekizumab attained a 75 % reduction in the PASI after 12 weeks, which compares with 82.5 % of the patients on ixekizumab every 4 weeks, 47.5 % of patients on etanercept, and 4.5 % of those given placebo [4].
To evaluate the maintenance and durability of the response, two studies continued for an additional 48 weeks in patients who at week 12 had responded to ixekizumab (both those on the biweekly plan and those on the monthly plan). These patients were randomly assigned to a maintenance dosage of ixekizumab every 4 weeks or to placebo. The best results were obtained in patients who took ixekizumab every 2 weeks for the first 12 weeks and every 4 weeks for the following 48 weeks. In this cohort, 78.3 % of the patients maintained a sPGA of 0 or 1, and about 58 % of these had maintained or achieved clear skin (sPGA = 0 in 58.8 % and 100 % reduction in PASI in 57.5 %). On the other hand, only about 7 % of the initial responders that switched to placebo had a sPGA of 0 or 1 [4], meaning that most of them relapsed after interruption of the treatment with ixekizumab.
The most common side effects are pain and redness at the injection site, and nose, throat or chest infections. It must not be given to patients who have potentially serious infections such as tuberculosis [1].
[1] EMA. Human Medicines: Taltx (ixekizumab), 02/05/2016 (last update: 15/12/2016), cited on 16/03/2017.
[2] Summary of Product Characteristics [FDA]: Taltz (ixekizumab), Eli Lilly and Co., Mar. 2016.
[3] Summary of Product Characteristics [TGA]: Taltz (ixekizumab), Eli Lilly Australia Pty. Ltd., Apr. 2017.
[4] Summary of Product Characteristics [EMA]: Taltz (ixekizumab), Eli Lilly Nederland B.V., Dec. 2016.
[5] Instructions for use: Taltz (ixekizumab) prefilled syringe. Mar. 2016.
[6] Instructions for use: Taltz (ixekizumab) prefilled pen
[7] Chow C., et al. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment. J Eur Acad Dermatol Venereol. 2015 Jul.; 29 (7):1406–1414.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.